Table 1 Baseline patient characteristics (n = 90)
Characteristic | N (%) |
|---|---|
Sex | |
Male | 48 (53.3) |
Female | 42 (46.7) |
Median age (range), years | 63 (27–79) |
ECOG performance status | |
0 | 82 (91.1) |
1, 2 | 8 (8.9) |
Site of primary tumor | |
RCC (cecum to the transverse colon) | 34 (37.8) |
LCRC (descending to the rectosigmoid colon) | 40 (44.4) |
Rectum | 16 (17.8) |
Mode of metastasis | |
Synchronous | 77 (85.6) |
Asynchronous | 13 (14.4) |
Sites of metastasis | |
Liver | 51 |
Lung | 38 |
Distant lymph nodes | 29 |
Peritoneum | 23 |
Histology | |
Differentiated | 83 (92.2) |
Undifferentiated | 7 (7.8) |
Number of metastases | |
1 | 37 (41.1) |
≥ 2 | 53 (58.9) |
Chemotherapy regimen | |
FOLFOX4/mFOLFOX6 or XELOX | 86 (95.6) |
FOLFIRI | 4 (4.4) |
Prior metastatectomy | |
Yes | 12 (13.3) |
No | 78 (86.7) |
Resection of primary tumor | |
Yes | 67 (74.4) |
No | 23 (25.6) |
Previous oxaliplatin treatment as adjuvant CTx | |
Yes | 13 (14.4) |
No | 77 (85.6) |
KRAS status (codon 12,13) | |
Wild-type | 47 (52.2) |
Mutant | 43 (47.8) |
RAS status (KRAS/NRAS) | |
Wild-type | 42 (46.7) |
Mutant | 48 (53.3) |
PIK3CA status | |
Wild-type | 82 (91.1) |
Mutant | 8 (8.9) |
BRAF status | |
Wild-type | 82 (91.1) |
Mutant | 8 (8.9) |